Fig. 6From: RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivityExpression of RRM2 and CDC6 rescues tamoxifen hypersensitivity in XBP1 knockout MCF7 cells. A Whole cell lysates from indicated RRM2 expressing cells were analysed by western blotting using antibodies against RRM2 and β-Actin. B Indicated RRM2 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show change in O.D at 490 nm. Data presented is mean ± S.D (n = 4). *p < 0.05, two-tailed unpaired t-test comparing respective time points. C Whole cell lysates from indicated (wild type and mutant) CDC6 expressing cells were subjected to western blotting using antibodies against CDC6 and β-Actin. D Indicated mutant CDC6 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show the change in O.D at 490 nm. Data presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01 from two-tailed unpaired t-test comparing respective time pointsBack to article page